- Citations, last 5 years
- 13.8k
- Works, last 5 years
- 2 014
- h-index
- 580
- Scientists listed
- 0
- Grants since 2016
- 630
Grants received
2022–2027 · research · R01
Investigation into the activation of multiple bnAb precursors using structure-designed immunogens and Ig knock-in mice
Daniel Kulp · The Wistar Institute · funded by National Institutes of Health
2022–2024 · program · P30
Augmenting T-cell immunotherapy outcomes in blood and solid tumor microenvironment in ART-suppressed HIV infection (immune/microenvironment)
Dario C Altieri · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers
Christine M. Eischen · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma
Jessie Villanueva · The Wistar Institute · funded by National Institutes of Health
2022–2026 · research · R01
ADNP mechanisms in R-loop regulation during differentiation
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
CTCF-dependent mechanisms of ATRX in neuronal differentiation
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2022–2024 · research · R21
Engineering HIV-resistant CAR T cells for a functional HIV cure
Daniel Thomas Claiborne · The Wistar Institute · funded by National Institutes of Health
2022–2025 · fellowship · Pew Biomedical Scholars
Pew Biomedical Scholar: Amelia Escolano (2022)
Amelia Escolano · The Wistar Institute · funded by Pew Charitable Trusts
2022–2023 · grant · S10
Purchase of a SARRP 200 Platform for Irradiation
Maureen E. Murphy · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers
Christine M. Eischen · The Wistar Institute · funded by National Institutes of Health
2022–2026 · research · R01
Epigenetic Regulation of Epstein-Barr Virus
Paul M. Lieberman · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma
Jessie Villanueva · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
CTCF-dependent mechanisms of ATRX in neuronal differentiation
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2022–2027 · grant · DP2
Manipulating Epitope Immunodominance and Tracking B-cell-Antigen Interactions for Vaccine Design.
Amelia Escolano · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
Investigation into the activation of multiple bnAb precursors using structure-designed immunogens and Ig knock-in mice
Amelia Escolano · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
ADNP mechanisms in R-loop regulation during differentiation
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2022–2026 · research · R01
Epigenetic Regulation of Epstein-Barr Virus
Paul M. Lieberman · The Wistar Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U19
Synthetic DNA-launched and adjuvanted Env immunogens for HIV
David B. Weiner · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
New control of oncogene activation in T-cell leukemia
Chengyu Liang · The Wistar Institute · funded by National Institutes of Health
2022–2027 · program · P01
Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticles
Jesper Pallesen · The Wistar Institute · funded by National Institutes of Health
2022–2027 · research · R01
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers
Christine M. Eischen · The Wistar Institute · funded by National Institutes of Health
2022–2027 · program · P01
Rapid, single-dose coronavirus vaccines via DNA-launched nanoparticles and genetic adjuvants for durable anti-coronavirus immunity
David B. Weiner · The Wistar Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U19
Administrative Core
David B. Weiner · The Wistar Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U19
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo
David B. Weiner · The Wistar Institute · funded by National Institutes of Health
2022–2027 · program · P01
Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites
Daniel Kulp · The Wistar Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U19
Vaccine and adjuvant Clinical GMP product development and DNA Technology platform enhancements
Trevor Smith · The Wistar Institute · funded by National Institutes of Health
2022–2027 · program · P01
Administrative Core
David B. Weiner · The Wistar Institute · funded by National Institutes of Health
2022–2027 · cooperative agreement · U19
Refinement of DNA-Launched NanoParticles decorated with Apex and CD4bs B cell lineage targeting Envs (DLNP-ACEs)
Daniel Kulp · The Wistar Institute · funded by National Institutes of Health
2021–2026 · research · R00
Integrated analyses of the epigenome to understand the molecular basis of hematopoietic malignancies
Avi Srivastava · The Wistar Institute · funded by National Institutes of Health
2021–2023 · career development · K22
Overcoming the hurdles to successful CAR T cell therapy for a functional HIV cure
Daniel Thomas Claiborne · The Wistar Institute · funded by National Institutes of Health
2021–2023 · cooperative agreement · UM1
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteers
Luis J Montaner · The Wistar Institute · funded by National Institutes of Health
2021–2023 · research · R21
Molecular and neurodevelopmental consequences of ADNP mutation
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2021–2023 · research · R21
The role of gut microbe-derived choline metabolites in driving the pro-inflammatory macrophage phenotype and restricting pancreatic cancer
Rahul Suresh Shinde · The Wistar Institute · funded by National Institutes of Health
2021–2023 · research · R21
Molecular and neurodevelopmental consequences of ADNP mutation
Kavitha Sarma · The Wistar Institute · funded by National Institutes of Health
2021–2026 · research · R01
Therapeutic targeting MDSC-mediated immune suppression in cancer
Valerian E Kagan · The Wistar Institute · funded by National Institutes of Health
2021–2025 · research · R01
Role of African-centric TP53 variant in higher H. pylori prevalence in African Americans
Daniel Thomas Claiborne · The Wistar Institute · funded by National Institutes of Health
2021–2026 · research · R01
Targeting Siglec-9/Sialoglycan Interactions to Enhance NK Functions During HIV Infection
Mohamed Abdel Mohsen · The Wistar Institute · funded by National Institutes of Health
2021–2026 · research · R01
Therapeutic targeting MDSC-mediated immune suppression in cancer
Valerian E Kagan · The Wistar Institute · funded by National Institutes of Health
2021–2026 · cooperative agreement · UM1
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy
Luis J Montaner · The Wistar Institute · funded by National Institutes of Health
2021–2026 · program · P50
SPORE in Skin Cancer
Ravi K Amaravadi · The Wistar Institute · funded by National Institutes of Health